Germany under the Tinfoil Hat? The associations of the big five personality traits and coronavirus conspiracy beliefs with the intention to get vaccinated.

BACKGROUND: The governments of democracies worldwide are relying on the active cooperation of their populations to combat COVID-19. Simultaneously, beliefs in conspiracy theories surrounding the pandemic have flourished. The present article examines the effects of the big five personality traits and conspiracy beliefs on the intention to get vaccinated against COVID-19 in Germany. METHODS: This correlational, cross-sectional mediation analysis was conducted using data from a nationwide German household panel (N = 1390). RESULTS: Openness to experience (ß = -.082, p = .004) and neuroticism (ß = .112, p < .001) showed direct effects on conspiracy beliefs, while conspiracy beliefs had the strongest effect on vaccination intention (ß = -.424, p < .001). Indirect positive effects of openness (ß = .035, p = .005) and negative effects of neuroticism (ß = -.047, p < .001) on the intention to get vaccinated via conspiracy beliefs were identified, with a mediation in the strict sense only for openness. No direct or total effect of the big five on vaccination intention could be found. CONCLUSIONS: The big five personality traits are associated, although indirectly, with the intention to be vaccinated. Compared with similar studies on the effects of the big five on COVID-19-related outcomes, we found slightly higher proportions of explained variance in conspiracy beliefs and significantly higher explained variance in vaccination intention. In order to increase the willingness to be vaccinated, targeted and nationwide uniform information measures should be provided addressing feelings of security, of not being excluded, and the activation of critical reasoning.

Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant morbidity and mortality worldwide. Despite a successful vaccination programme, the emergence of mutated variants that can escape current levels of immunity mean infections continue. Herein, we report the development of CT-P63, a broad-spectrum neutralizing monoclonal antibody. In vitro studies demonstrated potent neutralizing activity against the most prevalent variants, including Delta and the BA.1 and BA.2 sub-lineages of Omicron. In a transgenic mouse model, prophylactic CT-P63 significantly reduced wild-type viral titres in the respiratory tract and CT-P63 treatment proved efficacious against infection with Beta, Delta, and Omicron variants of SARS-CoV-2 with no detectable infectious virus in the lungs of treated animals. A randomized, double-blind, parallel-group, placebo-controlled, Phase I, single ascending dose study in healthy volunteers (NCT05017168) confirmed the safety, tolerability, and pharmacokinetics of CT-P63. Twenty-four participants were randomized and received the planned dose of CT-P63 or placebo. The safety and tolerability of CT-P63 were evaluated as primary objectives. Eight participants (33.3%) experienced a treatment-emergent adverse event (TEAE), including one grade ≥3 (blood creatine phosphokinase increased). There were no deaths, treatment-emergent serious adverse events, TEAEs of special interest, or TEAEs leading to study drug discontinuation in the CT-P63 groups. Serum CT-P63 concentrations rapidly peaked before declining in a biphasic manner and systemic exposure was dose proportional. Overall, CT-P63 was clinically safe and showed broad-spectrum neutralizing activity against SARS-CoV-2 variants in vitro and in vivo.